Article
Characteristics and Outcome of AKT1 E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry.
Cancer discovery - 1 Apr 2020
Smyth Lillian M, Zhou Qin, Nguyen Bastien, Yu Celeste, Lepisto Eva M, Arnedos Monica, Hasset Michael J, Lenoue-Newton Michele L, Blauvelt Natalie, Dogan Semih, Micheel Christine M, Wathoo Chetna, Horlings Hugo, Hudecek Jan, Gross Benjamin E, Kundra Ritika, Sweeney Shawn M, Gao JianJiong, Schultz Nikolaus, Zarski Andrew, Gardos Stuart M, Lee Jocelyn, Sheffler-Collins Seth, Park Ben H, Sawyers Charles L, André Fabrice, Levy Mia, Meric-Bernstam Funda, Bedard Philippe L, Iasonos Alexia, Schrag Deborah, Hyman David M
Abstract excerpt
AKT inhibitors have promising activity in AKT1 E17K-mutant estrogen receptor (ER)-positive metastatic breast cancer, but the natural history of this rare genomic subtype remains unknown. Utilizing AACR Project GENIE, an international clinicogenomic data-sharing consortium, we conducted a comparative analysis of clinical outcomes of patients with matched AKT1 E17K-mutant (n = 153) and AKT1-wild-type (n = 302)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.